1142 related articles for article (PubMed ID: 33839757)
1. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.
Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J
Front Immunol; 2024; 15():1244392. PubMed ID: 38694506
[TBL] [Abstract][Full Text] [Related]
3. Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer.
Yi L; Huang P; Zou X; Guo L; Gu Y; Wen C; Wu G
Pharmacol Res; 2020 Nov; 161():105144. PubMed ID: 32810627
[TBL] [Abstract][Full Text] [Related]
4. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
5. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
6. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
8. Characterization of stemness features and construction of a stemness subtype classifier to predict survival and treatment responses in lung squamous cell carcinoma.
Lai J; Lin X; Zheng H; Xie B; Fu D
BMC Cancer; 2023 Jun; 23(1):525. PubMed ID: 37291533
[TBL] [Abstract][Full Text] [Related]
9. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
Chai Y; Wang C; Liu W; Fan Y; Zhang Y
J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818
[TBL] [Abstract][Full Text] [Related]
10. Machine learning-identified stemness features and constructed stemness-related subtype with prognosis, chemotherapy, and immunotherapy responses for non-small cell lung cancer patients.
Liu M; Zhou R; Zou W; Yang Z; Li Q; Chen Z; Jiang L; Zhang J
Stem Cell Res Ther; 2023 Sep; 14(1):238. PubMed ID: 37674202
[TBL] [Abstract][Full Text] [Related]
11. Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.
Chen D; Liu J; Zang L; Xiao T; Zhang X; Li Z; Zhu H; Gao W; Yu X
Int J Biol Sci; 2022; 18(1):360-373. PubMed ID: 34975338
[TBL] [Abstract][Full Text] [Related]
12. Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
Liu B; Liu J; Liao Y; Jin C; Zhang Z; Zhao J; Liu K; Huang H; Cao H; Cheng Q
Med Sci Monit; 2019 May; 25():3624-3635. PubMed ID: 31094363
[TBL] [Abstract][Full Text] [Related]
13. A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.
Chai R; Zhang K; Wang K; Li G; Huang R; Zhao Z; Liu Y; Chen J
J Cancer Res Clin Oncol; 2018 Mar; 144(3):439-447. PubMed ID: 29299749
[TBL] [Abstract][Full Text] [Related]
14. Artificial neural network identified a 20-gene panel in predicting immunotherapy response and survival benefits after anti-PD1/PD-L1 treatment in glioblastoma patients.
Wang Y; Wang Z; Guo X; Cao Y; Xing H; Wang Y; Xing B; Wang Y; Yao Y; Ma W
Cancer Med; 2024 May; 13(9):e7218. PubMed ID: 38733169
[TBL] [Abstract][Full Text] [Related]
15. CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells.
Drachsler M; Kleber S; Mateos A; Volk K; Mohr N; Chen S; Cirovic B; Tüttenberg J; Gieffers C; Sykora J; Wirtz CR; Mueller W; Synowitz M; Martin-Villalba A
Cell Death Dis; 2016 Apr; 7(4):e2209. PubMed ID: 27124583
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
Yan W; Liu Y; Yang P; Wang Z; You Y; Jiang T
Oncotarget; 2015 May; 6(13):11676-82. PubMed ID: 25869098
[TBL] [Abstract][Full Text] [Related]
17. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma.
Sun Z; Zhao Y; Wei Y; Ding X; Tan C; Wang C
Front Immunol; 2022; 13():939523. PubMed ID: 36091049
[TBL] [Abstract][Full Text] [Related]
19. Nuclear Respiratory Factor 1 (NRF1) Transcriptional Activity-Driven Gene Signature Association with Severity of Astrocytoma and Poor Prognosis of Glioblastoma.
Bhawe K; Felty Q; Yoo C; Ehtesham NZ; Hasnain SE; Singh VP; Mohapatra I; Roy D
Mol Neurobiol; 2020 Sep; 57(9):3827-3845. PubMed ID: 32594352
[TBL] [Abstract][Full Text] [Related]
20. MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells.
Pellecchia S; De Martino M; Esposito F; Quintavalle C; Fusco A; Pallante P
Cell Cycle; 2021 Apr; 20(7):716-729. PubMed ID: 33734003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]